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Background: Lung transplantation (LTx) is still limited by organ shortage. To expand the donor pool, lung retrieval
from non-heart-beating donors (NHBD) was introduced into clinical practice recently. However, primary graft
dysfunction with inactivation of endogenous surfactant due to ischemia/reperfusion-injury is a major cause of early
mortality. Furthermore, donor-derived human mesenchymal stem cell (hMSC) expansion and fibrotic differentiation
in the allograft results in bronchiolitis obliterans syndrome (BOS), a leading cause of post-LTx long-term mortality.
Therefore, pretreatment of NHBD with recipient-specific bone-marrow-(BM)-derived hMSC might have the potential
to both improve the postischemic allograft function and influence the long-term development of BOS by the
numerous paracrine, immunomodulating and tissue-remodeling properties especially on type-II-pneumocytes of
hMSC.
Methods: Asystolic pigs (n = 5/group) were ventilated for 3 h of warm ischemia (groups 2–4). 50x106
mesenchymal-stem-cells (MSC) were administered in the pulmonary artery (group 3) or nebulized endobronchially
(group 4) before lung preservation. Following left-lung-transplantation, grafts were reperfused, pulmonary-vascular-
resistance (PVR), oxygenation and dynamic-lung-compliance (DLC) were monitored and compared to control-lungs
(group 2) and sham-controls (group 1). To prove and localize hMSC in the lung, cryosections were counter-stained.
Intra-alveolar edema was determined stereologically. Statistics comprised ANOVA with repeated measurements.
Results: Oxygenation (p = 0.001) and PVR (p = 0.009) following endovascular application of hMSC were significantly
inferior compared to Sham controls, whereas DLC was significantly higher in endobronchially pretreated lungs
(p = 0.045) with overall sham-comparable outcome regarding oxygenation and PVR. Stereology revealed low
intrapulmonary edema in all groups (p > 0.05). In cryosections of both unreperfused and reperfused grafts, hMSC
were localized in vessels of alveolar septa (endovascular application) and alveolar lumen (endobronchial application),
respectively.
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Conclusions: Preischemic deposition of hMSC in donor lungs is feasible and effective, and endobronchial application
is associated with significantly better DLC as compared to sham controls. In contrast, transvascular hMSC delivery
results in inferior oxygenation and PVR. In the long term perspective, due to immunomodulatory, paracrine and
tissue-remodeling effects on epithelial and endothelial restitution, an endobronchial NHBD allograft-pretreatment with
autologous mesenchymal-stem-cells to attenuate limiting bronchiolitis-obliterans-syndrome in the long-term perspective
might be promising in clinical lung transplantation. Subsequent work with chronic experiments is initiated to further
elucidate this important field.
Keywords: Non-heart-beating donors, Perfadex lung preservation, Mesenchymal stem cell therapy, Ischemia-reperfusion
injury, Donor pretreatmentBackground
Although lung transplantation has been proven to be an
effective standard therapy for patients with different end-
stage pulmonary diseases, significant scarcity of suitable
donor organs [1] still limits an unrestricted application.
Lung retrieval from non-heart-beating donors (NHBD) of-
fers the potential to increase the number of available or-
gans significantly and was shown to result in excellent
experimental results [2,3]. Meanwhile, this approach is
established in clinical practice in different countries [3-6].
However, primary graft dysfunction due to ischemia/re-
perfusion-(I/R)-injury is still a major cause of early mortal-
ity and morbidity following pulmonary transplantation [7],
and bronchiolitis obliterans syndrome (BOS) is a leading
cause of long-term mortality in lung transplant recipients
[8]. Therefore, donor pretreatment strategies [9] especially
in Extended Criteria Donors [10,11] or NHBD lungs
[12,13] become continuously important to attenuate the
deleterious I/R-injury which is known to be associated
with both inactivation of intraalveolar surfactant [14–16]
and damage to the integrity of surfactant-producing alveo-
lar epithelial type II (AE2-) cells [17]. In the latter context
it was shown that the beneficial role of hMSC transplant-
ation into the injured lung may be partly mediated by dif-
ferentiation of hMSC into AE2-cells [18,19]. Furthermore,
growing evidence exists that donor-derived tissue-specific
mesenchymal stem cell (hMSC) expansion and fibrotic
differentiation is associated with development of BOS in
human lung allografts [20,21]. Therefore, a cell-based pre-
treatment strategy of the NHBD with recipient-specific
hMSC appears to be very attractive and might have the
potential to both improve the postischemic surfactant
function and influence the long-term development of
BOS by the numerous paracrine, immunomodulating
and tissue-remodeling properties of hMSC [18,22–24].
Obviously, the variable degree of homing capacity and
homing duration are crucial parameters for the extent
of positive hMSC effects [25,26], therefore successful
intrapulmonary deposition to facilitate migration of de-
livered MSC seem to be important factors. So far, how-
ever, no comparative studies exist whether a vascular orendobronchial application of exogenous hMSC into the
NHBD lung is superior in order to facilitate the postu-
lated beneficial effects. Therefore it was the aim of this
preliminary study to evaluate the impact of both deliv-
ery routes on success of intrapulmonary deposition and
short-term postischemic outcome following experimen-
tal lung transplantation. Generally, intra-allograft de-
position of recipient-derived hMSC might represent a
novel and promising strategy to further optimise early
and long-term function also of the pulmonary allograft
by specific cell therapy as it was recently shown in hep-
atic transplantation [27].
Methods
Bone-marrow-derived human mesenchymal stem cells
(hMSC)
As the isolation and large scale expansion of porcine
MSC is not established, bone marrow was harvested
from consecutive patients scheduled for elective coronary
artery bypass grafting surgery. The institutional ethics
committee of the University Hospital Cologne approved
the procedure of bone marrow aspiration for this study
and patients gave written informed consent. Immediately
before sternotomy up to 40 ml of sternal bone marrow
(BM) aspirate was collected using a bone marrow harvest
needle (Gallini Inc., Mantova, Italy) and heparinized sy-
ringes. Bone marrow derived hMSC were isolated, cul-
tured and confirmed as previously described by our
group [28]. Briefly, the aspirates were filtered, mono-
nuclear cells were isolated by density gradient centrifu-
gation and seeded at a density of 106 cells per cm2 in
T75 cell culture flasks (BD) in specialized hMSC media
(PAN Biotech, Aidenbach, Germany) supplemented
with penicillin/streptomycin (1:100, Life Technologies,
Darmstadt, Germany). Cells were grown at 37°C and
5% CO2 in a humidified incubator (Binder, Tuttlingen,
Germany) and passaged when confluent. To generate
cell numbers sufficient for large animal cell transplanta-
tions, 1-5x106 hMSC were seeded into multilayered cell
culture vessels (Corning, Wiesbaden, Germany; total
cell culture surface area: 3.180 cm2) and cultured for
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with fluorescent, paramagnetic microbeads (Bangs La-
boratories, Fishers, IN, USA) by incubation overnight.
For harvesting, cells were washed three times with PBS
(Life Technologies) and detached with 0.05% trypsin
(Life Technologies). After assessing total cell number
using a hemacytometer the cells were labeled with the
fluorescent vital stain DiI (Life Technologies) according
to the manufacturer’s instructions and then resus-
pended in PBS at a concentration of 5 million cells per
ml. The total number of hMSC for transplantation was
5x107 (2.27-2.5 million hMSC per kilogram of body
weight) according to current evidence in the literature
[27,29].
All hMSC were phenotypically validated by flow cytome-
try using a FACS Calibur (BD) as published by our group
previously (28). Samples (2x105 cells) were stained with
fluorochrome-conjugated (phycoerythrin, PE; fluorescein
isothiocyanate, FITC) antibodies CD45-FITC (Miltenyi Bio-
tec, Bergisch Gladbach, Germany), CD73-PE, CD90-FITC
(BD), CD105-PE (Beckmann Coulter, Krefeld, Germany)
and matching isotype controls at recommended dilutions.
At least 100.000 cells were included in the data analysis
using MACSquantify software v2.5 (Miltenyi Biotec).
Large animal single lung transplantation model
Female domestic pigs weighing from 20–22 kg were ran-
domized into 4 groups of 5 donor animals, each with an-
other 5 animals in each group weighing from 28–32 kg
as organ recipients. In order to prevent a limiting size-
mismatch, donor animals were chosen to be somewhat
smaller as compared to the recipients. One group served
as a sham-operated control group (group 1) and was
prone to surgical dissection of hilar structures, but nei-
ther organ preservation nor transplantation were per-
formed. In the 3 NHBD test groups, asystolic pigs were
ventilated for 3 h of warm ischemic time (groups 2–4). No
approval codes on animal research needed to be obtained
according to the corresponding ethical committee.
Surgical procedure
a) Donor preparation
All animals were premedicated with ketamine 10%
(20 mg/kg), atropine (0.04 mg/kg) and propofol
(3 mg/kg). Pigs were then put in the supine position,
intubated and mechanically ventilated with 50%
oxygen in a pressure-controlled mode with a peak
inspiratory pressure of 20 mmHg, a rate of 18
breaths per minute, an inspiratory/exspiratory ratio
of 1:1 and a PEEP of 8 mmHg. Anesthesia was
continued with infusion of fentanyl (0,3 μg/kg/min),
midazolam (20 μg/kg/min) and pancuronium
(10 μg/kg/min). All animals received 200 IU/kg ofheparin intravenously. A median sternotomy was
performed and the pericardium was opened
longitudinally. A perfusion cannula with a sideport
to measure the perfusion pressure was placed
through the auricle into the left atrium. In the
NHBD groups 2, 3 and 4, cardiac fibrillation was
induced electrically, and the cadaver was ventilated
at an FiO2 of 0.5 and left at room temperature 3 hours
of warm ischemic time. In groups 3 and 4 only,
50x106 human bone-marrow-derived mesenchymal
stem cells (hMSC) in 10 ml of normal saline were
administered during the final 10-min of NHBD-
ventilation using either the pulmonary artery
(group 3) or were nebulized endobronchially
(group 4) using a mobile ultrasonic nebulizer
(Nebu-tec GmbH, Elsenfeld, Germany). This
nebulizer was connected to the inspiratory limb of
the ventilator system and can be used for all types
of currently available clinical ventilators. Antegrade
perfusion via the pulmonary artery was started
directly after hMSC application, and an 8-minute
period was required to infuse 1800 ml LPD solution
at 4°C with a maximum flushing pressure of
14 mmHg. Ventilation was continued throughout
the entire perfusion period. After completion of the
preservation, the heart-lung bloc was excised with
both lungs inflated in an endinspiratory state and
stored at 4°C for 3 hours.
b) Recipient/Sham preparation
The anesthetic regimen was identical to the donor
procedure. A Swan-Ganz catheter (Baxter Healthcare
Corp., Irvine, CA, USA) and a catheter to monitor the
arterial pressure (Vygon, France) were placed into
the internal jugular vein and right carotid artery,
respectively. All animals were placed in a right
decubitus position, and a left thoracotomy was
performed in the fifth intercostal space. The
pulmonary bifurcation, left main bronchus and left
pulmonary veins were dissected in all groups.
After clamping of the left pulmonary artery and
bronchus, the left pulmonary veins were ligated and
pneumonectomy was performed in the NHBD
groups 2–4 only. The left donor lung was isolated
from the heart-lung bloc and prepared for
implantation with a large atrial cuff and full length
of both the pulmonary artery and left main
bronchus. Implantation of the donor lung started
with the bronchial anastomosis using a running
suture with 4–0 Prolene (Ethicon Inc., Somerville,
NJ, USA) followed by the arterial anastomosis with
a running suture of 6–0 Prolene. After clamping of
the left atrium, a recipient atrial cuff was designed
and anastomosed to the donor atrial cuff using a
running suture of 5–0 Prolene. Prior to reperfusion,
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pulmonary artery was then unclamped and the graft
reventilated in a pressure controlled mode with a
peak inspiratory pressure of 30 mmHg using a PEEP
of 10 mmHg with a respiratory rate of 18/min. After
15 minutes of reperfusion, the previously dissected
contralateral right pulmonary artery and bronchus
were clamped with a vascular clamp both in the
sham-operated control-group and all test groups.
All lungs were reperfused for 4 hours followed by
termination of the experiment by intravenous
injection of magnesium sulfate.Functional analysis
In all experiments, arterial and pulmonary artery pres-
sures as well as central venous and left atrial pressures
were recorded continuously. Dynamic lung compliance
was monitored by the ventilator (Dräger Medical Inc.,
Lübeck, Germany). An arterial and mixed-venous blood
gas analysis was performed initially and in 30 minute in-
tervals during the reperfusion period. Cardiac output
was measured continuously by the Swan-Ganz catheter,
and systemic and pulmonary vascular resistances were
calculated.
Wheat-germ-agglutinin (WGA) labelling of cryo sections
Samples of the native right lung – after hMSC application
according to the respective group, flush preservation with
LPD solution and cold storage of 3 hours – were directly
fixed by vascular perfusion of 4% paraformaldehyde, were
washed in 1 M PBS-Dulbecco (Biochrom AG; L182-50)
for 3 days at 4°C and were incubated in O.C.T. compound
(Sakura Tissue-Tek; 4583) in cryo molds (Sakura Tissue-
Tek; 4566) for 4 hours at room temperature. Thereafter,
the samples were frozen in 2-methylbutane (Roth; 3927.1)
on dry ice and 6 μm thin cryo sections were made on a
Leica CM 3050 S microtome. After drying, the slices were
labelled with WGA-FITC (Sigma; L4895) 1:150 in PBS in-
cluding 5% BSA (Serva; 11930) for 1 hour and the nuclei
were stained with DAPI (Molecular Probes; D1306) for
additional 15 minutes at room temperature. After washing
with PBS images were taken on a Zeiss Axiophot with the
F46-00 ET-Set filter for DAPI, the F36-525 HC-Set filter
for WGA and the F36-503 HC-Set filter for MSCs from
AHF Analysetechnik (Tuebingen, Germany) and proc-
essed with Photoshop CS6.
Fixation, sampling and processing of the left lung
allograft
At the end of the reperfusion, biopsy samples (approx.
0.5 cm3) were acquired from the upper lobe of the left
lung. These samples were immediately embedded in O.
C.T. compound (Sakura Tissue-Tek, Staufen, Germany)
and snap frozen in 2-methylbutane (Roth, Karlsruhe,Germany) on dry ice. Cryo sections (10 μm) were prepared
using a CM1950 cryotome (Leica, Wetzlar, Germany),
stained with 4′,6-diamidino-2-phenylindole (DAPI, Life
Technologies, Darmstadt, Germany) and microscopically
analyzed (Ti-U microscope and NIS 3.4 software, Nikon,
Düsseldorf, Germany). Then, the entire left lung was fixed
by perfusion with 2 l of a fixative containing 4% formalde-
hyde (prepared from freshly depolymerized paraformalde-
hyde) and 0.1% glutaraldehyde in 0.2 M Hepes buffer.
Perfusion pressure was 15 cm H2O. During fixation, infla-
tion of the lung was maintained at a constant pressure of
12 cm H2O. Afterwards, the fixed lung was excised, the
volume was estimated by fluid displacement based on
buoyancy [29,30] and the lung was then cut into slices of
2 cm thickness. To ensure that every part of the lung had
an equal chance of being included in the analysis, system-
atic uniform random sampling was performed by project-
ing a transparent uniform point grid on each tissue slice
[31]. Whenever a point hit the surface of a lung slice a tis-
sue block of approximately 1 cm3 was excised at the given
location and stored in fresh and cold fixative [14]. The
samples were subsequently washed in 0.1 M sodium caco-
dylate, postfixed in osmium tetroxide, washed again in so-
dium cacodylate and distilled water, stained en bloc in half-
saturated watery uranyl acetate over night, dehydrated in
an ascending acetone series and finally embedded in a gly-
col methacrylate resin (Technovit 8100, Heraeus Kulzer,
Wehrheim, Germany). Sections of 1.5 μm thickness were
cut from the tissue blocks and stained with methylene
blue.
Stereology
All stereological analyses were carried out using a DM
6000B light microscope (Leica, Wetzlar, Germany) with
motorized stage controlled by a computer-assisted stereol-
ogy system (newCAST, Visiopharm, Horsholm, Denmark).
Test fields for further analysis were gathered by systematic
uniform random sampling from at least five different tis-
sue blocks per animal. A point grid with an adjusted num-
ber of test points was projected onto each test field and
the volume fraction of intra-alveolar edema fluid per
unit volume of the parenchyma as the reference space
(VV(ed/par)) was estimated by counting points hitting
the intra-alveolar edema (Ped) and those points hitting
the reference volume (Pref ). The volume fraction was esti-
mated by VV:= Ped/Pref and converted to the total volume
by multiplication with the reference volume [32,33].
Animal care
All animals received humane care in compliance with
the European Convention on Animal Care and with the
“Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals”
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National Research Council, and published by the National
Academy Press, revised 1996. The study was approved by
the institutional ethics committee.
Statistical analysis
All data are expressed as mean ± SD and were analyzed
with the Statistical Program of Social Sciences (IBM
SPSS Statistics, Version 20.0). Continous data were ana-
lyzed using ANOVA with repeated measures. For evalu-
ation of data without repeated measures, standard
analysis of variance was used. Statistical significance was
assumed with a p-value <0.05.
Results
1. Functional analysisFig
meThere was no mortality in the study groups. All
Sham-operated animals presented with excellent
oxygenation (pO2/FiO2: 472 ± 121 mmHg, Figure 1),
dynamic lung compliance (DLC, 12.6 ± 3.1 ml/mbar,
Figure 2) and pulmonary vascular resistance (507 ±
167 dynes*m2*sec−5, Figure 3). Compared with sham
animals, non-heart-beating animals without MSC
application presented with not significantly different
outcome in terms of oxygenation (p = 0.087), PVR
(p = 0,61) and DLC (p = 0.38) as we have shown
previously (12). After vascular hMSC application
(group 3), PVR (p = 0.09), oxygenation (p = 0.06) and
compliance (p = 0.88) were comparable to NHBD
without hMSC pretreatment (group 2), however
PVR in group 3 (p = 0.009) was significantly higher
and oxygenation significantly lower (p = 0.001) as
compared to sham controls. In contrast, bronchial
hMSC-application (group 4) resulted in PVR
(p = 0.99) and oxygenation (p = 0.057) comparable
with sham and showed significantly better values in
dynamic lung compliance as compared to sham
(p = 0.045).ure 1 Postischemic oxygenation (pO2/FiO2) of transplanted pig NH
an ± standard deviation. ANOVA (repeated measures): Sham versus MSC2. Histological analysis
The volume fraction of intraalveolar edema referred
to total lung parenchyma [Vv(ed/par), Figure 4] was
overall low with values of 0.0198 ± 0.002 (sham
group 1), 0.0136 ± 0.0096 (group 2), 0.0100 ± 0.0068
(group 3) and 0.0166 ± 0.0073 (group 4, p = 0.123).
Following endovascular application, corresponding
hMSC in both preserved/unreperfused right lungs
(Figure 5) and preserved/reperfused left grafts
(Figure 6) were detected within vessels of the
alveolar septa, whereas after endobronchial
application, deposition of hMSC was proven to be in
the alveolar lumen, respectively.
Discussion
Ischemia-/reperfusion injury (IRI) of pulmonary allo-
grafts is characterized by increased alveolar epithelial
and especially AE2-cell damage [34–37]. Furthermore,
disturbances at the endothelial level are also considered
to be a consequence of alveolar injury and, especially, of
damage to AE2-cells [35]. This corresponds to the con-
cept developed by Mason and Williams [38] who defined
type II pneumocytes as the “defender of the alveolus”.
The multiple functions of type II cells comprise surfac-
tant synthesis, storage and secretion, ion- and water-
transport, synthesis of growth factors etc. [39], therefore,
AE2-cells are considered to be an essential element in
stabilizing alveolar integrity and lung function. In ac-
cordance with several findings of our own group, strat-
egies for improvements in pulmonary preservation were
focused on maintenance of the blood-air barrier and es-
pecially type-II-cell functions [36,37]. Aside from eco-
nomically expensive application of exogenous surfactant
in order to supplement the IRI-induced significantly al-
tered intraalveolar surfactant pool [16,40–42], an in-
novative cell therapy with recipient-based hMSC might
represent a promising strategy due to paracrine, immuno-
modulating and tissue-remodeling properties of hMSC
[18,22–24] which include a trans-differentiation of hMSCBD lungs during the observation period of 4 hours. Values are
vasc: p = 0.001.
Figure 2 Postischemic dynamic lung compliance of transplanted pig NHBD lungs during the observation period of 4 hours. Values are
mean ± standard deviation. ANOVA (repeated measures):. Sham versus MSCbron: p = 0.045.
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AE2-cells [18,19,24]. In contrast to embryonic stem cells,
bone marrow-derived hMSC have the distinct advantage
of being abundant, easy to access with reasonable inva-
siveness and readily cultivated to a number sufficient for
intrapulmonary application into the donor lung without
ethical issues. With respect to the desirable potential ef-
fects on the epithelial layer, an application via the trans-
bronchial route rather than a vascular approach is of
theoretical advantage as the hMSC-homing-capacity and
-duration depend on localisation and migration of deliv-
ered hMSC [25,26]. In previously published findings of
our group, an endobronchial application of iloprost into
donor lungs resulted in significantly improved dynamic
lung compliance and overall optimised lung preservation
[12,43,44]. Correspondingly, in the current series of endo-
bronchial application of hMSC, dynamic lung compliance
was significantly higher as compared to Sham controls,
and both pulmonary vascular resistance and oxygenation
showed a clear tendency towards better values as com-
pared to the transvascular route using the pulmonary ar-
tery which might indicate a beneficial short-term effect ofFigure 3 Postischemic pulmonary vascular resistance of transplanted
are mean ± standard deviation. ANOVA (repeated measures): Sham versus Mthis application mode even for hMSC application. How-
ever, hMSC will mainly exert the postulated beneficial ef-
fects in the intermediate and long-term phase following
lung transplantation. Therefore, it was the aim of this pilot
study to proof the general concept of intrapulmonary
hMSC deposition into the NHBD lung by detection of ad-
ministered stem cells in the recipient in a lung transplant-
ation screening model with an initial reperfusion period of
only 4 hours. In fluorescence microscopy we were able to
document the explicit intrapulmonary deposition of the
hMSC in both reperfused and unreperfused lungs al-
though the total number of 50 million administered cells
was rather low with regard to the total volume of a pig
lung. In addition to the cited immediate effects in terms of
significantly superior dynamic lung compliance, significant
intermediate and long-term effects may therefore be pos-
tulated. As the immunogenicity of hMSC is low due to
only low expression of MHC class I and II proteins in
combination with lack of T-cell co-stimulating molecules
CD80 und CD86, hMSC in general defy clearance by the
recipient immune system and can be used in patients
without HLA-matching [45,46]. For the same reason wepig NHBD lungs during the observation period of 4 hours. Values
SCvasc: p = 0.009.
Figure 4 Stereological quantification of intraalveolar edema
(volume fraction referred to total lung parenchyma) of
transplanted pig NHBD lungs after the observation period of
4 hours. Values are mean ± standard deviation. Differences are
statistically not significant (ANOVA : p = 0.251).
Wittwer et al. Journal of Cardiothoracic Surgery 2014, 9:151 Page 7 of 11
http://www.cardiothoracicsurgery.org/content/9/1/151used xenogenic human MSC in this pig lung model as we
are not able to isolate and expand porcine MSC so far.
When the recipient-based hMSC would be obtained from
waiting-list patients by regular bone-marrow aspiration
and cultured to significant numbers in the increasingly ex-
tended waiting period for lung transplantation, then a sig-
nificant immunologic response in the donor lung is clearly
no issue [47].
Aside from the capability of hMSC to transform into
other cell types, numerous paracrine factors like secre-
tion of anti-inflammatory cytokines as IL-10 oder local
growth factors as VEGF play a major role in regenerative
medicine [18]. Depression in VEGF protein expressionFigure 5 Detection of transplanted hMSC in the corresponding comp
alveolar septa (left), following endobronchial (nebulized) application
(right). Scale bar = 10 μm.was shown by us to be an early event after IR and indi-
cates increased alveolar epithelial and especially type II
cell damage [35], therefore an increase in VEGF secre-
tion and a reduced rate of apoptosis of lung parenchy-
mal cells might be an important result of hMSC therapy
[18,23]. Also, an increased secretion of keratinocyte-
growth factor (KGF) with corresponding proliferation of
AE2 cells and subsequent increase in surfactant produc-
tion [48,49] in combination with direct paracrine effects
on AE2 cells in terms of restoration of epithelial protein
permeability by increased secretion of Angiopoietin-1
[50] are known beneficial effects of pulmonary hMSC
therapy and might explain the experienced superior out-
come in terms of dynamic lung compliance following
endobronchial application of hMSC in our series. How-
ever, the optimal dose of hMSC, which is experimentally
chosen in the area of 50 × 106 per animal [27,29] and
which was also used in an ex-vivo perfused human lung
experiment [48], has still to be finally determined.
The major cause of long-term morbidity and mortality
in lung transplant recipients is the bronchiolitis obliter-
ans syndrome (BOS) which is a form of chronic rejection
characterized by an irreversible airway obstruction that
affects about 50% of recipients surviving 5 and more years
[1,51]. In the pathogenesis of BOS, progressive fibroproli-
feration and accumulation of extracellular matrix culmin-
ate in a profound fibrotic obliteration of the airways
[8,52]. Recent findings suggest an important pathogenic
role for donor-derived lung allograft-resident hMSC in
fibroproliferative responses resulting in allograft remodel-
ing [20,21,53]. As these allograft-resident hMSC wereartments: following endovascular application in vessels of
in the alveolar or bronchial lumen of native right NHBD lungs
Figure 6 Detection of transplanted hMSC in the corresponding compartments: following endovascular application in vessels of
alveolar septa (left), following endobronchial (nebulized) application in the alveolar or bronchial lumen of transplanted and reperfused
NHBD lungs (left). Scale bar = 10 μm.
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eral unique embryonic lung mesenchyme-associated tran-
scription factors like FOXF1, HOXA5 and HOXB5 as
compared with bone-marrow-derived hMSC, it is con-
cluded that those cells are derived from donor embryonic
mesenchyme and represent a locally resident tissue-
specific progenitor cell [20]. As a hypothesis, application
of recipient-specific bone marrow-derived MSC into
the non-heart-beating donor lung might offer an in-
novative and easily applicable method to prophylactic-
ally initiate a specific autologous cell therapy in the
pulmonary allograft before the onset of clinically sig-
nificant ischemia-reperfusion injury (IRI). Whether the
extent of chronic allograft dysfunction on terms of BOS
can be positively influenced by this approach could eas-
ily be examined experimentally by bronchoalveolar lav-
age in the intermediate and long-term follow-up which
is a standard method to obtain pulmonary hMSC by
plastic adherence [21]. As a potential result, the onset
and/or extent of the deleterious BOS might be influ-
enced by specific donor-lung cell therapy and could re-
sult in improvement of long-term allograft function
and patient survival which is currently significantly lim-
ited with increasing BOS status. The exact mode of ac-
tion of transplanted hMSC in this promising approach
still remains unclear. However, in most studies dealing
with hMSC in the treatment of lung injury, engraftment
rates of transplanted hMSC were <5% [50], suggesting
that the magnitude of hMSC on repair appeared out of
proportion to the number of donor-derived lung-
specific hMSC. Therefore, the therapeutic benefit oftransplanted hMSC might comprise a combination of
paracrine effects that could stimulate the expansion,
homing and differentiation of endogenous stem cells on
one hand, and the direct differentiation of the trans-
planted autologous hMSC towards alveolar epithelial
cells and other cell types on the other hand [47].
Recently, a novel form of chronic lung allograft dys-
function (CLAD) was described by Sato et al. [54,55]. In
contrast to BOS, which is characterized by small airway
fibrosis and obstructive physiology, restrictive allograft
syndrome (RAS) is characterized by peripheral lung fi-
brosis and restrictive physiology [54]. Importantly, RAS
accounts for about 30% of CLAD, and survival of RAS-
patients seems to be significantly shorter than that of
BOS [54,56]. The cause of RAS seems to be multifactor-
ial and, similar to ARDS, an insult to the allograft such
as infection or rejection leads to acute uncontrollable in-
flammation followed by fibrosis. In the pathogenesis of
CLAD in general, activation of stromal resident cells
such as epithelial cells and fibroblasts, is considered to
be important [57], and specifically in RAS patients the
stem cell population in terms of epithelial progenitors
seems to be depleted over time since lung transplant-
ation which might contribute to the increased vulner-
ability to damage or to the irreversible damage after an
additional injury [58]. As the vicious cycle of immune-
responsive cells and activated stromal resident cells
through cytokines, chemokines and adhesion molecules
may lead to irreversible tissue organization and fibrosis,
an appropriate therapeutic target of CLAD in general
and RAS in specific should not simply be the cause (i.e.
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pathway of uncontrollable inflammation and subsequent
fibrosis which seems to be related to the depletion of the
stem-cell population in the allograft [55,58].
Conclusion
A specific donor-lung cell therapy with effective pre-
ischemic intrapulmonary hMSC transplantation might
be a promising therapy to positively influence the onset
and/or the extent of both the deleterious bronchiolitis
obliterans (BOS) and restrictive allograft syndrome (RAS).
Most importantly, such a hMSC-based therapy has a sig-
nificant safety advantage as no adverse differentiation of
transplanted MSC has been observed, as opposed to po-
tential teratoma formation from pluripotent cells and their
derivatives [59,60].
Consequently, according to a well recognized review
by Moodley et al. [61], studies like our current work
who have the potential to elucidate further pathways
that mediate the action of bone-marrow derived mesen-
chymal stem cells are generally considered to be “vital to
future therapeutic strategies in the treatment of lung dis-
ease”. However, limitations of this study comprise the
short reperfusion period of 4 hours in this acute phase
screening model, the low number of transplanted hMSC
and the missing vitality testing of transplanted MSC. All
aspects will be specifically addressed in future experi-
ments in a chronic lung transplantation modell which
will be established in our group.
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